Introduction {#sec1}
============

The human gastrointestinal tract represents one of the most densely populated microbial communities on earth, containing as many microbial cells as there are human cells in the body and \>150 times more bacterial genes than the human genome ([@bib1], [@bib2]). Among healthy adults, the large intestine contains the densest community of microorganisms, containing upward of 10^11^ microbial cells/g of colonic contents. Beneficial contributions of these microbes include salvaging energy by metabolizing nondigestable dietary fibers to produce butyrate, a preferential metabolite for colonocytes. However, the gastrointestinal microbiota can also contribute to deleterious effects, such as gastrointestinal and systemic inflammation and the development of noncommunicable diseases, including obesity, cardiovascular disease, and cancer ([@bib2]).

Epidemiologic data suggest that a Western diet pattern, rich in saturated fat and simple sugars and devoid of an appreciable amount of dietary fiber, is associated with increased risk of obesity, cardiovascular disease, and colorectal and liver cancer ([@bib5], [@bib6]). Alternatively, diets rich in nuts, a source of dietary fiber and unsaturated fatty acids, are associated with a reduced risk of total and cause-specific mortality from cancer and heart disease ([@bib7]). Habitual dietary patterns contribute to the composition and function of the human gastrointestinal microbiome ([@bib8]). Importantly, short-term changes in diet can alter the microbiome: switching from a vegetarian diet to a diet high in saturated fat and processed meats rapidly (within 2--4 d) changed fecal microbial profiles, reduced fecal butyrate concentrations, and increased bile acid secretion in healthy adults ([@bib8], [@bib9]). Although the consumption of dietary fiber and prebiotics have been shown to differentially affect the human gastrointestinal microbiome ([@bib10]), there is a dearth of knowledge on the impact of specific whole foods on the human microbiota.

Previously, a complete feeding trial that used a randomized controlled crossover design was completed to determine the metabolizable energy of walnuts when consumed as part of a typical American diet ([@bib13]). The metabolizable energy of walnuts was 21% lower than that predicted by the Atwater values because of reduced digestibility of macronutrients. Because the nutrients that escape digestion in the small intestine enter the large intestine and provide substrates for fermentation by colonic microbiota, our objective was to elucidate the effects of the reduced digestibility of walnuts on the fecal microbiota, fecal bile acids, and metabolic markers of health in healthy adults.

Methods {#sec2}
=======

This study is a follow-up to a previously conducted trial ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT01832909). Details of the design and results of the primary study, which assessed the metabolizable energy of walnuts by using bomb calorimetry of diets, walnuts, fecal, and urine samples, were reported elsewhere ([@bib13]). Herein, secondary outcomes, including fecal microbiota and bile acid concentrations, and metabolic health variables are reported. Briefly, a randomized, crossover, controlled-feeding study with two 3-wk dietary interventions was conducted at the Beltsville Human Nutrition Research Center. The fully controlled dietary feeding intervention provided the same base diet during each treatment condition; the base diet was unsupplemented during the control condition and supplemented with 1.5 servings (42 g) of walnut halves and pieces daily during the walnut treatment condition. This amount is consistent with the FDA qualified health claim for walnut consumption on coronary artery disease. The base diet provided 17% of energy from protein, 29% of energy from fat, and 54% of energy from carbohydrates. The base diet foods were reduced in equal proportions during the walnut treatment condition to achieve isocaloric food intake during the 2 diet periods. Diets were scaled according to the energy requirements of the study participants for weight maintenance throughout the study. Participants completed both of the dietary intervention conditions with a 1-wk compliance break between each condition. The treatment order was randomized by dividing participants by sex and by using a random-number generator. Participants completed daily questionnaires for dietary deviations, medications, unusual exercise, and general well-being.

 {#sec2-1}

### Participants {#sec2-1-1}

Study participants were recruited from the Washington, DC area. Interested volunteers completed a health history questionnaire; were measured for height, weight, and blood pressure; and provided fasting blood and urine samples for the analysis of lipids, glucose, a comprehensive metabolic panel, and complete blood count and urinalysis. Potential volunteers were excluded for any of the following reasons: \<25 or \>75 y of age, BMI (kg/m^2^) of \<20 or \>38, fasting glucose ≥126 mg/dL, blood pressure ≥160/100 mm Hg, fasting total serum blood cholesterol ≥280 mg/dL, and fasting serum TGs ≥300 mg/dL; if they were smokers or allergic to walnuts; if they abused alcohol; if they had kidney disease, liver disease, gout, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, diabetes requiring medication, unstable body weight over the past 12 mo, malabsorption syndrome; or if they were women who were pregnant, lactating, or had given birth in the past 12 mo. All of the study procedures were reviewed and approved by the Institutional Review Board of the Medstar Research Institute and were in accord with the Declaration of Helsinki. All of the participants provided written consent forms.

### Sample collection and analyses {#sec2-1-2}

Blood samples were collected at the beginning and end of each treatment condition after a 12-h overnight fast. Serum samples were assayed to assess total cholesterol, LDL cholesterol, HDL cholesterol, TGs, and glucose by using enzymatic procedures (Vitros 5,1; Ortho-Clinical Diagnostics, Inc.); and inflammatory markers (IL-6, C-reactive protein \[CRP\], serum amyloid A \[SAA\], soluble adhesion molecules \[soluble intercellular adhesion molecule (sICAM) and soluble vascular cell adhesion molecule (sVCAM)\]) were measured by using sandwich-type immunoassay methods (Meso Scientific Discovery). Plasma noncholesterol sterol (squalene, desmosterol, lathosterol, cholestenol, campesterol, and β-sitosterol) concentrations were quantified by GC and expressed relative to total cholesterol ([@bib14], [@bib15]).

Fecal samples were collected at the beginning and end of each dietary period. Upon collection, samples were homogenized in a bag, placed in aliquots, and stored at --80°C at the Beltsville Human Nutrition Research Center before overnight shipping on dry ice to the University of Illinois. Fecal DNA was isolated with the use of a PowerLyzer PowerSoil DNA Isolation Kit (MoBio Laboratories) according to the manufacturer\'s instructions. Bacterial (16S V4 region, 505f/806r) ([@bib16]), archaeal (349f/806r), and fungal (ITS1--ITS4) ([@bib17]) genes were amplified on a Fluidigm Access Array then sequenced on a MiSeq with the use of v3 reagents (Illumina, Inc.) in the WM Keck Center for Biotechnology, University of Illinois, as previously described ([@bib18]).

Sequence data were analyzed with QIIME 1.8.0; sequences were clustered into operational taxonomic units (OTUs) with the use of closed reference OTU picking against the 13-8 Greengenes database (97% similarity) for the bacterial and archaeal sequences ([@bib19]). Fungal OTUs were generated with the use of the open reference OTU-picking algorithm against the UNITE OTUs ITS 12_11 reference database. Additional quality filtering ([@bib20]) was undertaken before rarefying the bacterial sequences to an even sampling depth of 35,957 sequences/sample to assess α and β diversity measures as well as the impact of treatment on OTU relative abundances. Predicted bacterial functional capacity was assessed with the use of PICRUSt, version 1.1.1, and the KEGG Pathway Database ([@bib21]).

Freeze-dried fecal aliquots were shipped overnight to the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University for analysis of bile acids. Briefly, total lipids were extracted overnight by using a modified Folch method ([@bib22]) with nor-deoxycholic acid (0.4 μg/μL; Steraloids) as the internal standard. Samples were analyzed on an ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry UHPLC-QTOF MS (Agilent Technologies) equipped with a 1290 series LC system and a 6550 iFunnel QTOF MS detector. Samples were injected onto the column (Zorbax Eclipse Plus C18; 2.1 × 50 mm, 1.8 μm) maintained at 25°C, and the bile acids eluted with the use of a 40-min isocratic mobile phase at 0.25 mL/min, from 10 mM ammonium acetate and 0.1% ammonium hydroxide in 100% methanol (pH = 7.5). The primary (cholic and chenodeoxycholic acids) and secondary (lithocholic and deoxycholic acids) bile acids were identified on the basis of molecular formula, retention times, and mass (MassHunter Qualitative Analysis software) and quantified (micrograms per milligram) with the use of the respective standard curves. Interassay CVs were 1.9% for cholic acid, 5.4% for chenodeoxycholic acid, 2.4% for deoxycholic acid and 4.5% for lithocholic acid.

### Statistical analysis {#sec2-1-3}

Differences in serum (lipids, glucose, inflammatory markers, and sterols) and fecal (microbial abundances and bile acids) measures at the end of each dietary treatment period were analyzed with the use of a mixed-effects ANOVA with treatment as the fixed effect and participant and period as the random effects. Statistical analysis was conducted in SAS version 9.4 (SAS Institute, Inc.). The UNIVARIATE procedure and Shapiro-Wilk statistic were used to test for data normality, and logarithmic transformations were utilized as needed. Changes from baseline scores were calculated in the walnut group to assess relations between change in bacterial abundances and change in serum cholesterol concentrations. Bivariate correlations were conducted to assess the relations between bacterial abundances and secondary bile acid concentrations at the end of the walnut consumption period. Pearson\'s correlations were used for normally distributed variables and Spearman correlation for nonnormally distributed variables. Wilcoxon's rank-sum tests were conducted to compare predicted bacterial butanoate metabolism (KEGG 00650) and secondary bile acid biosynthesis (KEGG 00121) gene counts at the end of the walnut and control periods. Linear discriminant analysis effect size (LEfSE; Galaxy version 1.0) was used to assess KEGG Pathway Hierarchy Level 2 and 3 metabolism data. For all of the analyses, *P* ≤ 0.05 was considered significant and *P* ≤ 0.10 was considered to be a trend.

Results {#sec3}
=======

All 18 participants, 10 men and 8 women, who were randomly assigned completed the study (**[Supplemental Figure 1](#sup1){ref-type="supplementary-material"}**). Participants had a mean ± SEM BMI of 28.8 ± 0.9 and were aged 53.1 ± 2.2 y ([**Table 1**](#tbl1){ref-type="table"}).

###### 

Baseline characteristics of the 10 men and 8 women who consumed control and walnut diets, each for 3 wk^[1](#tb1fn1){ref-type="fn"}^

  Characteristics                   Mean ± SEM   Range
  --------------------------------- ------------ ------------
  Age, y                            53.1 ± 2.2   35.0--67.8
  BMI, kg/m^2^                      28.8 ± 0.9   20.2--34.9
  Serum LDL cholesterol, mg/dL      121 ± 6.4    65.5--175
  Serum HDL cholesterol, mg/dL      51.4 ± 2.9   29.1--77.9
  Serum TGs, mg/dL                  116 ± 12.7   39.2--203
  Serum glucose, mg/dL              92.7 ± 1.7   89.4--116
  Systolic blood pressure, mm Hg    117 ± 3.4    98--144
  Diastolic blood pressure, mm Hg   71.4 ± 2.2   60--90

^1^Serum analytes were assessed after an overnight fast. Adapted with permission from reference [@bib13].

The mean ± SD bacterial OTU was 88,880 ± 47,427, with a maximum of 288,079 counts and a minimum of 35,957 counts/sample. At the phylum level, the majority of sequences were dominated by Firmicutes, Bacteroidetes, and Actinobacteria (84.4%, 6.5%, and 5.4%, respectively). Thirty-five families were identified. Six families (Lachnospiraceae, Ruminococcaceae, an undefined family in the Clostridales order, Bacteroidaceae, Bifodobacteriaceae, and Verrucomicrobiaceae) comprised \>90% of all families. Seventy-two genera were classified, with 22 representing \>96% of sequences and 15 representing \<1%; *Bacteroides, Blautia, Coprococcus, Ruminococcus*, unclassified Ruminococcaceae, unclassified Clostridiales, and unclassified Lachnospiraceae represented 74% of sequences. The mean ± SD archaeal OTU was 19,205 ± 42,075, with a maximum of 163,351 counts and a minimum of 3 counts/sample. Treatment did not affect archaea abundances. Fungal OTUs were present in lower abundances with a mean ± SD of 854 ± 2765 counts/sample. The minimum was 1 OTU (13 samples) and the maximum was 17,404 sequences. Treatment did not affect fungal abundances.

Walnut consumption did not affect bacterial α diversity measures, including phylogenetic diversity, observed OTUs, or richness and evenness. For β diversity, weighted principal coordinates analysis of UniFrac distances between samples based on their 97% OTU composition and abundances showed that bacterial communities were affected by walnut consumption (*P *= 0.03). At the phylum level, compared with the end of the control period, walnut consumption increased (*P* = 0.04) the relative abundance of Firmicutes and decreased (*P* = 0.02) the relative abundance of Actinobacteria ([**Table 2**](#tbl2){ref-type="table"}). Among bacterial genera, *Faecalibacterium, Clostridium, Roseburia*, and *Dialister* were increased (*P *\< 0.05) at the end of the walnut intervention period compared with the control ( [Table 2](#tbl2){ref-type="table"}). Alternatively, the relative abundances of *Ruminococcus, Dorea, Oscillospira*, and *Bifidobacterium* were lower (*P *\< 0.05) at the end of the control diet period than at the end of the walnut diet period ([Table 2](#tbl2){ref-type="table"}). The number of predicted bacterial butanoate metabolism genes was not different at the end of the walnut period (488,366 ± 168,601) compared with after the control period (570,743 ± 151,243) (*P *= 0.11).

###### 

Fecal bacterial phyla and genera of adults who consumed control and walnut diets, each for 3 wk, in a crossover design^[1](#tb2fn1){ref-type="fn"}^

                                                          Percentage of sequences                 
  ------------------------------------------------------- ------------------------- ------ ------ --------
  Firmicutes                                              82.4                      87.2   2.83   0.04
   *Blautia*                                              8.33                      8.23   0.82   0.82
   *Coprococcus*                                          7.56                      6.99   0.74   0.25
   *Ruminococcus*                                         6.19                      5.17   0.85   \<0.01
   *Dorea*                                                3.21                      2.58   0.39   \<0.01
   *Streptococcus*                                        2.07                      1.98   1.03   0.80
   *Faecalibacterium*                                     1.45                      2.77   0.59   0.02
   *Roseburia*                                            0.79                      1.32   0.29   \<0.01
   *Clostridium*                                          0.72                      1.07   0.13   0.01
   *Oscillospira*^[2](#tb2fn2){ref-type="fn"}^            0.51                      0.37   0.06   0.04
   *Dialister*                                            0.28                      0.73   0.25   0.04
   *Lactobacillus*                                        0.28                      0.46   0.36   0.34
   *Lachnospira*                                          0.23                      0.26   0.06   0.63
   *Anaerostipes*                                         0.22                      0.26   0.05   0.30
  Bacteroidetes                                           5.72                      5.20   2.10   0.62
   *Bacteroides*                                          4.88                      4.60   1.81   0.77
   *Parabacteroides*                                      0.13                      0.16   0.07   0.48
  Actinobacteria                                          8.19                      5.00   1.90   0.02
   *Bifidobacterium*                                      6.43                      3.97   1.83   0.03
   *Collinsella*^[2](#tb2fn2){ref-type="fn"}^             0.10                      0.05   0.26   0.07
  Verrucomicrobia                                         3.26                      1.77   0.96   0.41
   *Akkermansia*                                          3.26                      1.77   0.96   0.41
  Proteobacteria                                          0.23                      0.58   0.13   0.13
  Firmicutes:Bacteroidetes^[3](#tb2fn3){ref-type="fn"}^   1.64                      1.73   0.21   0.54

^1^Values are least-square means ± SEMs unless otherwise indicated; *n *= 18. Treatment effects were evaluated with the use of a mixed-model ANOVA.

^2^Values are mean log-normalized sequence abundances ± SEs.

^3^Values are least-square means ± SEMs of log-transformed Firmicutes-to-Bacteroidetes ratio.

Primary bile acids were not affected by treatment. Microbially derived secondary bile acids, deoxycholic acid and lithocholic acid, were reduced by 25% and 45%, respectively, in the walnut group compared with the control (*P *\< 0.01) ([**Table 3**](#tbl3){ref-type="table"}). The number of predicted bacterial biosynthesis of secondary bile acids genes tended (*P *= 0.09) to be lower at the end of the walnut period (36,331 ± 12,256) than at the end of the control period (42,714 ± 11,605).

###### 

Fecal bile acid concentration of freeze-dried feces collected from adults who consumed control and walnut diets, each for 3 wk^[1](#tb3fn1){ref-type="fn"}^

                                 Control   Walnut   SEM    *P*
  ------------------------------ --------- -------- ------ --------
  Cholic acid, µg/mg             0.32      0.28     0.09   0.54
  Chenodeoxycholic acid, µg/mg   0.20      0.15     0.05   0.19
  Deoxycholic acid, µg/mg        2.61      1.96     0.23   \<0.01
  Lithocholic acid, µg/mg        0.76      0.41     0.06   \<0.01

^1^Values are least-square means ± pooled SEMs; *n *= 18 participants in a crossover design. Treatment effects were evaluated with the use of a mixed-model ANOVA.

Serum total cholesterol concentrations were lower (*P* = 0.03) by 7 mg/dL (4% reduction) and LDL-cholesterol concentrations were lower (*P* \< 0.01) by 9 mg/dL (7% reduction) after walnut consumption compared with the control ([**Table 4**](#tbl4){ref-type="table"}). Other metabolic variables were unaffected by walnut consumption. Serum campesterol was lower (*P* = 0.01) by 10 μmol/mmol (6% reduction), and lathosterol concentrations tended to be lower (*P* = 0.06) during the walnut period compared with the control ([**Table 5**](#tbl5){ref-type="table"}). There were no associations between the change in total cholesterol or LDL cholesterol and microbes affected by walnut consumption ([**Table 6**](#tbl6){ref-type="table"}). Lithocholic acid concentrations were positively associated with the relative abundances of *Dorea* (*r* = 0.46, *P* = 0.05) ([**Figure 1**A](#fig1){ref-type="fig"}) at the end of the walnut treatment period and tended to be negatively associated with *Roseburia* (*r* = −0.42, *P* = 0.08) ([Figure 1B](#fig1){ref-type="fig"}). There were no associations between deoxycholic acid concentrations and bacteria affected by walnut consumption ([**Table 7**](#tbl7){ref-type="table"}). Other predicted bacterial metabolism gene counts were unaffected by walnut consumption (**[Supplemental Tables 1 and 2](#sup1){ref-type="supplementary-material"}**).

![Bivariate correlations between fecal *Dorea* (A) and *Roseburia* (B) sequence abundances and lithocholic acid concentrations at the end of the walnut treatment period.](nxy004fig1){#fig1}

###### 

Serum analytes of adults who consumed control and walnut diets, each for 3 wk^[1](#tb4fn1){ref-type="fn"}^

                           Control   Walnut   SEM    *P*
  ------------------------ --------- -------- ------ --------
  Cholesterol, mg/dL       194       187      7.1    0.03
  LDL cholesterol, mg/dL   117       108      6.5    \<0.01
  HDL cholesterol, mg/dL   48.0      48.5     3.0    0.51
  TGs, mg/dL               92.4      89.8     8.2    0.35
  Glucose, mg/dL           99.7      99.5     1.6    0.79
  IL-6, pg/mL              1.43      1.36     0.18   0.32
  CRP, ng/mL               3330      3830     1290   0.37
  SAA, ng/mL               5490      6104     2790   0.52
  sICAM, ng/mL             336       334      16.4   0.68
  sVCAM, ng/mL             503       502      32.6   0.86

^1^Values are least-square means ± pooled SEMs; *n *= 18 participants in a crossover design. Treatment effects were evaluated with the use of a mixed-model ANOVA. CRP, C-reactive protein; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule.

###### 

Serum noncholesterol sterol concentration of adults who consumed control and walnut diets, each for 3 wk^[1](#tb5fn1){ref-type="fn"}^

                                            Control   Walnut   SEM    *P*
  ----------------------------------------- --------- -------- ------ ------
  Squalene, 100 μmol/mmol cholesterol       15.9      14.0     1.87   0.25
  Desmosterol, 100 μmol/mmol cholesterol    105       97.9     8.49   0.29
  Lathosterol, 100 μmol/mmol cholesterol    183       169      26.8   0.06
  Cholestanol, 100 μmol/mmol cholesterol    331       342      17.1   0.47
  Campesterol, 100 μmol/mmol cholesterol    169       159      19.8   0.01
  β-Sitosterol, 100 μmol/mmol cholesterol   75.4      77.9     10.7   0.14

^1^Values are least-square means ± pooled SEMs; *n *= 18 participants in a crossover design. Treatment effects were evaluated with the use of a mixed-model ANOVA.

###### 

Associations between fecal microbiota and serum cholesterol and LDL cholesterol in the walnut treatment group^[1](#tb6fn1){ref-type="fn"}^

                       Cholesterol, mg/dL   LDL cholesterol, mg/dL           
  -------------------- -------------------- ------------------------ ------- ------
  *Ruminococcus*       −0.39                0.10                     −0.33   0.19
  *Dorea*              −0.03                0.89                     −0.13   0.62
  *Faecalibacterium*   0.26                 0.30                     0.31    0.21
  *Roseburia*          0.14                 0.58                     0.10    0.70
  *Clostridium*        0.20                 0.43                     −0.02   0.94
  *Oscillospira*       −0.21                0.41                     −0.39   0.11
  *Dialister*          −0.20                0.42                     −0.16   0.52
  *Bifidobacterium*    0.17                 0.49                     0.03    0.92

^1^Relations between change from baseline fecal bacterial sequence abundances that were significantly affected by walnut consumption and serum total cholesterol and LDL cholesterol concentrations were assessed in the walnut treatment group (*n *= 18) with the use of bivariate correlations (Spearman\'s ρ).

###### 

Bivariate correlations between fecal bacterial sequence abundances and secondary bile acid concentrations at the end of the walnut consumption period among the 18 adult participants

                       Deoxycholic acid, µg/mg   Lithocholic acid, µg/mg           
  -------------------- ------------------------- ------------------------- ------- ------
  *Ruminococcus*       0.07                      0.77                      0.08    0.77
  *Dorea*              0.25                      0.32                      0.46    0.05
  *Faecalibacterium*   −0.27                     0.28                      −0.25   0.33
  *Roseburia*          −0.32                     0.19                      −0.42   0.08
  *Clostridium*        −0.29                     0.25                      −0.21   0.41
  *Oscillospira*       −0.15                     0.55                      0.07    0.78
  *Dialister*          −0.24                     0.34                      −0.17   0.49
  *Bifidobacterium*    −0.13                     0.62                      −0.12   0.63

Discussion {#sec4}
==========

To our knowledge, this is the first study to examine the impact of walnut consumption on the human fecal microbiota and bacterial metabolites and metabolic health. Specifically, in a completely controlled dietary intervention, the addition of 42 g walnut halves/d increased the relative abundance of Firmicutes species in the Clostridium clusters XIVa and IV, including *Faecalibacterium, Roseburia*, and *Clostridium*. These results are supported by preclinical studies indicating that walnuts increased the relative abundances of Firmicutes, including the genera *Clostridium* ([@bib23]) and *Roseburia* ([@bib24]). In vitro work has shown that *Faecalibacterium* and *Roseburia* spp. display butyryl CoA:acetate CoA transferase activity and ferment fiber to produce butyrate ([@bib25]). Although in vitro fermentation of walnuts has not been investigated to our knowledge, finely ground almonds have been shown to increase butyrate concentrations in vitro ([@bib28]). However, because our results also showed a reduction in the relative abundance of *Bifidobacteria*, a microbe that produces acetate, a necessary metabolite for butyrate production through butyryl CoA:acetate CoA transferase enzyme activity, walnut consumption may not have resulted in an overall increase in butyrate concentrations. Furthermore, our results showed that there was not a significant difference in predicted bacterial butyrate metabolism gene abundances between the walnut and control groups. Additional in vitro and in vivo research is necessary to determine if walnuts increase microbial butyrate production and gastrointestinal butyrate concentration, respectively.

The human liver synthesizes 2 primary bile acids, cholic acid and chenodeoxycholic acid, which are converted to secondary bile acids---deoxycholic and lithocholic acid, respectively---by intestinal bacteria ([@bib29]). Western diets, which are rich in saturated fat and low in dietary fiber, result in increased amounts of secondary bile acids in the colon and biliary pool ([@bib30]), and evidence suggests that deoxycholic and lithocholic acids are toxic bile acids associated with gastrointestinal diseases and colon cancer ([@bib31], [@bib32]). The gastrointestinal microbiota has been shown to regulate the metabolism and synthesis of bile acids via the nuclear bile acid receptor farnesoid X receptor ([@bib33]). Dietary fatty acid composition has also been shown to differentially affect the interactions between bile acids and the gastrointestinal microbiota ([@bib34]). Herein, we report significant reductions in microbially derived, proinflammatory secondary bile acids (e.g., deoxycholic acid and lithocholic acid) after walnut consumption, and a trend for a reduction in predicted bacterial secondary bile acid biosynthesis gene abundances in the walnut group compared with the control group (*P *= 0.09). Both reduced secondary bile acid concentrations and increased *Faecalibacterium* have been shown to reduce gut inflammation ([@bib31], [@bib35]). Furthermore, a rodent study showed that walnut consumption reduces colon tumor development and size and led to changes in the cecal microbiota ([@bib36]). Thus, the findings in this report provide additional support for the connections between diet, the gastrointestinal microbiota, and colonic health.

Related to the effects on walnut consumption on cardiovascular health, similar to previous reports our results show that walnut consumption reduced total and LDL-cholesterol concentrations ([@bib37]). Although walnut consumption reduced total and LDL-cholesterol concentrations and changed the composition of the fecal microbiota, there were no significant relations between microbes affected by walnut consumption and total and LDL cholesterol. These results suggest that total and LDL cholesterol are not directly related to gastrointestinal microbes, which is consistent with a cross-sectional study in 893 subjects that reported that neither LDL cholesterol nor total cholesterol were related to the microbiota (5, 6). Interestingly, *Dorea* and *Roseburia* tended to be related to the concentration of the secondary bile acid lithocholic acid, suggesting that the associations between the gastrointestinal microbiota and cardiovascular health may be related to the microbial metabolism of bile acids and subsequent signally through farnesoid X receptor.

PUFAs have antimicrobial properties, including the inhibition of bacterial FA synthesis ([@bib38]), growth, and mucus adhesion ([@bib39]). n--3 FA supplementation modulated rodent fecal microbiota by suppressing growth of bacteria associated with obesity and inflammation ([@bib40]). PUFAs can also modulate the gastrointestinal microbiota due to differing abilities of bacteria to metabolize long-chain FAs. For example, in vitro studies have shown that *Roseburia* spp. are involved in the process of converting linoleic acid to its conjugated form ([@bib41]). Thus, the increase in *Roseburia* in the present study may be related to its ability to metabolize FAs.

In addition to providing a source of fiber and unsaturated FAs, walnuts are also high in ellagic acid. Gastrointestinal bacteria can metabolize ellagic acid to produce urolithins, which can enter the enterohepatic circulation and have anti-inflammatory and beneficial vascular effects ([@bib44]). Walnut extract, including polyphenols and ellagic acid, has shown positive effects on endothelial health in vitro ([@bib47]). To our knowledge, studies have only investigated the effects of walnut, tree nut, and polyphenol consumption on either the presence of urolithin byproducts through urinalysis or the microbiome through analysis of fecal samples ([@bib48], [@bib49]), whereas little is known about the roles of specific bacteria on polyphenol metabolism and urolithin production. Fermentation of pomegranate tannins including ellagic acid in vitro resulted in increased microbial fermentation, thereby reducing pH ([@bib50]). Others have shown that *Bifidobacterium fragilis* is inhibited by the presence of ellagic acid ([@bib50]), which could explain the decrease in the relative abundance of *Bifidobacterium* spp. after the walnut diet condition in the present study.

Although the age range for this study population was fairly broad (35--68 y), 13 of the 18 participants were aged ≥50 y. Thus, the characteristics of the microbiota would generally be reflective of a slightly older population. Because *Faecalibacterium* and *Roseburia* have been reported to be negatively associated with age and *Oscillospira* to be positively associated with age ([@bib51], [@bib52]), the consumption of walnuts may help to slow age-related changes in the microbiota. However, because semi-supercentenarians show enriched *Bifidobacterium* ([@bib52]), and walnut consumption reduced the relative abundance of *Bifidobacterium*, additional research is necessary to assess the effects of walnut consumption and the microbiota in the context of aging.

The strength of this study is the use of a complete feeding, randomized, controlled crossover trial with a washout period to assess the impact of walnut consumption on physiologic and microbiological outcomes among human subjects. Study limitations include the lack of fecal fermentative end products, including short-chain FAs, and metagenomic analyses to assess the functional capacity of the microbiota.

In summary, walnut consumption affected the gastrointestinal microbiota and microbially derived secondary bile acids and reduced serum total and LDL cholesterol in healthy adults. These results suggest that the gastrointestinal microbiota may contribute to the underlying mechanisms of the beneficial health effects of walnut consumption, including cardiometabolic and gastrointestinal health.

Supplementary Material
======================
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Click here for additional data file.
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